Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing
NCT03344809 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 127
Last updated 2024-04-22
Summary
To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.
Conditions
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Principal Investigators
-
Sunil Iyengar · Royal Marsden NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-31
- Primary Completion
- 2023-04-30
- Completion
- 2026-05-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
NCT02856646 ·Status: COMPLETED
-
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
NCT03758989 ·Status: RECRUITING ·Phase: PHASE2
-
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
NCT01660776 ·Status: COMPLETED
-
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
NCT06674096 ·Status: RECRUITING ·Phase: PHASE2
-
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
NCT02267590 ·Status: UNKNOWN
-
T-Cell Project: Epidemiologic Component
NCT00705809 ·Status: COMPLETED
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NCT06693830 ·Status: RECRUITING ·Phase: NA
-
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941 ·Status: ACTIVE_NOT_RECRUITING
-
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
NCT01287923 ·Status: COMPLETED
-
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT05464823 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders
NCT05803616 ·Status: RECRUITING
-
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
NCT01324596 ·Status: COMPLETED ·Phase: PHASE3
-
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
NCT06526065 ·Status: RECRUITING
-
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
NCT06090162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419 ·Status: TERMINATED ·Phase: PHASE1
-
Cell Free DNA in Mature B-cell Lymphoma
NCT04088422 ·Status: RECRUITING
-
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
NCT00042666 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
NCT04183569 ·Status: UNKNOWN
-
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 ·Status: COMPLETED
-
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
NCT01478269 ·Status: COMPLETED
-
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
NCT04434833 ·Status: UNKNOWN
-
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
NCT04982471 ·Status: TERMINATED
-
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
NCT04827004 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN